Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Total Liabilities (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Total Liabilities for 14 consecutive years, with $188.8 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 17.32% to $188.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $188.8 million through Dec 2025, up 17.32% year-over-year, with the annual reading at $188.8 million for FY2025, 17.32% up from the prior year.
  • Total Liabilities hit $188.8 million in Q4 2025 for Corcept Therapeutics, down from $191.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $191.7 million in Q3 2025 to a low of $41.6 million in Q1 2021.
  • Historically, Total Liabilities has averaged $105.9 million across 5 years, with a median of $105.5 million in 2023.
  • Biggest five-year swings in Total Liabilities: decreased 0.92% in 2021 and later surged 120.97% in 2023.
  • Year by year, Total Liabilities stood at $47.9 million in 2021, then skyrocketed by 70.15% to $81.6 million in 2022, then surged by 40.72% to $114.8 million in 2023, then surged by 40.2% to $161.0 million in 2024, then increased by 17.32% to $188.8 million in 2025.
  • Business Quant data shows Total Liabilities for CORT at $188.8 million in Q4 2025, $191.7 million in Q3 2025, and $165.9 million in Q2 2025.